Key Insights
The global Vaccine Contract Manufacturing Organization (CMO) market is poised for robust expansion, projected to reach approximately USD 3,510 million in 2025 with an impressive Compound Annual Growth Rate (CAGR) of 11.18% through 2033. This significant growth is fueled by a confluence of escalating global health concerns, including the persistent threat of pandemics and the rising incidence of chronic diseases, which are driving an unprecedented demand for vaccine development and production. Pharmaceutical and biotechnology companies are increasingly outsourcing their manufacturing operations to specialized CMOs to leverage their expertise, advanced technologies, and capacity, thereby accelerating time-to-market for critical vaccines. This trend is further amplified by the continuous innovation in vaccine technologies, such as the burgeoning field of RNA vaccines, which require specialized manufacturing capabilities. The market is witnessing substantial investments in upstream processes, particularly in advanced expression systems like mammalian and bacterial platforms, to cater to the diverse needs of vaccine developers, from early-stage preclinical research to large-scale commercial production. Analytical and quality control studies, along with fill and finish operations, are critical downstream segments attracting considerable attention and investment, ensuring the safety and efficacy of vaccine products.
Vaccine Contract Manufacturing Industry Market Size (In Billion)
The Vaccine CMO market's dynamism is also shaped by evolving regulatory landscapes and the strategic imperatives of companies seeking to manage costs and operational complexities. The demand spans both human and veterinary applications, with the human use segment dominating due to the larger scale and higher value associated with human vaccines. Key market players, including Catalent, Lonza Group AG, and CJ CheilJedang Corporation, are actively expanding their capabilities and geographical footprints to capitalize on this burgeoning market. Geographically, North America and Europe are expected to remain dominant markets, driven by established biopharmaceutical hubs and strong research and development ecosystems. However, the Asia Pacific region, particularly China and India, is emerging as a significant growth engine, owing to its cost-effectiveness, increasing manufacturing prowess, and expanding domestic vaccine demands. The market's trajectory is further supported by the increasing focus on diversifying manufacturing capabilities to include novel vaccine types and delivery systems, ensuring a resilient global vaccine supply chain.
Vaccine Contract Manufacturing Industry Company Market Share
Unlocking Global Health: The Comprehensive Vaccine Contract Manufacturing Industry Report
This in-depth report provides a definitive analysis of the Vaccine Contract Manufacturing Organization (CMO) market, a critical and rapidly evolving sector powering global health initiatives. Spanning a study period of 2019–2033, with 2025 as the base and estimated year, and a forecast period of 2025–2033, this report delves into historical trends (2019–2024) to offer unparalleled insights for stakeholders seeking to navigate this dynamic landscape. The Vaccine Contract Manufacturing Industry is poised for significant expansion, driven by increasing demand for specialized manufacturing capabilities, the rise of novel vaccine technologies, and strategic partnerships.
Vaccine Contract Manufacturing Industry Market Composition & Trends
The Vaccine Contract Manufacturing Industry exhibits a moderately concentrated market, with leading players leveraging their specialized expertise and large-scale capabilities. Innovation in vaccine development, particularly in RNA Vaccines and Subunit Vaccines, acts as a significant catalyst, driving demand for flexible and advanced contract manufacturing solutions. The regulatory landscape remains a crucial factor, with stringent quality control and adherence to Good Manufacturing Practices (GMP) paramount for CMOs. Substitute products are less prevalent in the vaccine space, given the highly regulated and specialized nature of vaccine production. End-users, primarily pharmaceutical and biotechnology companies, rely heavily on CMOs to scale production, manage complex manufacturing processes, and accelerate time-to-market. Mergers and Acquisitions (M&A) are prominent, with estimated M&A deal values exceeding Millions as established players acquire niche capabilities or expand their global footprint to capture market share. The market share distribution is influenced by the ability of CMOs to handle diverse vaccine types and scales of operation.
Vaccine Contract Manufacturing Industry Industry Evolution
The Vaccine Contract Manufacturing Industry has undergone a remarkable evolution, driven by the persistent need for efficient and scalable vaccine production. Historically, CMOs focused on traditional Inactivated Vaccines and Live-attenuated Vaccines, catering to established infectious disease threats. However, the advent of novel vaccine platforms, especially RNA Vaccines, has fundamentally reshaped the industry. This technological shift has necessitated significant investment in specialized facilities and expertise, leading to a surge in demand for advanced contract development and manufacturing organizations (CDMOs).
The market growth trajectory has been significantly accelerated by global health crises, such as the COVID-19 pandemic, which underscored the critical role of CMOs in rapid vaccine deployment. This period saw unprecedented demand for large-scale Commercial production across all vaccine types, pushing the boundaries of manufacturing capacity. Technological advancements in upstream processing, including sophisticated Mammalian Expression Systems and Bacterial Expression Systems, alongside refined downstream processing techniques like advanced purification and fill and finish operations, have been pivotal.
Shifting consumer demands, influenced by an aging global population and an increasing awareness of preventative healthcare, further propel the need for a diverse range of vaccines. The veterinary sector also represents a growing segment, demanding specialized vaccine manufacturing for animal health. The industry's evolution is characterized by a continuous push for cost-efficiency, speed, and flexibility, enabling pharmaceutical companies to focus on R&D while outsourcing complex manufacturing processes. Growth rates have been substantial, with many CMOs reporting revenue increases in the double digits, driven by new contracts and the expansion of existing ones. Adoption metrics for new manufacturing technologies are high, as CMOs strive to stay at the forefront of vaccine production capabilities. The overall Vaccine Contract Manufacturing Industry is projected to continue its upward trajectory, fueled by ongoing innovation and global health priorities.
Leading Regions, Countries, or Segments in Vaccine Contract Manufacturing Industry
The Vaccine Contract Manufacturing Industry sees distinct dominance across various segments, driven by unique factors.
Vaccine Type Dominance:
- RNA Vaccines: This segment is experiencing exponential growth due to its inherent flexibility and rapid development capabilities, as exemplified by the COVID-19 pandemic. The increasing investment in mRNA vaccine manufacturing facilities globally is a key driver.
- Subunit Vaccines: These vaccines continue to hold a significant market share due to their established safety profiles and broad applicability across various diseases. Advances in recombinant DNA technology have further enhanced their manufacturing efficiency.
- Inactivated Vaccines: While a mature segment, the ongoing need for influenza and other inactivated vaccines ensures their continued relevance and demand for contract manufacturing.
Process Dominance:
- Downstream Processing: This area, encompassing critical steps like Analytical and QC Studies, Fill and Finish, and Packaging, is a major bottleneck and area of expertise for CMOs. The demand for sterile fill and finish operations for biologics and vaccines is exceptionally high, with significant investment in advanced automation and containment technologies.
- Upstream Processing: The selection of Mammalian Expression Systems and Bacterial Expression Systems often dictates the type of vaccine being produced and requires specialized infrastructure and expertise, making it a key differentiator for CMOs.
Scale of Operations Dominance:
- Commercial Scale: The surging global demand for approved vaccines across human and veterinary applications makes Commercial scale manufacturing the most significant segment in terms of revenue and investment. This necessitates large-scale bioreactors, purification suites, and extensive fill and finish lines.
- Clinical Scale: The continuous pipeline of new vaccine candidates ensures sustained demand for Clinical scale manufacturing, enabling pharmaceutical companies to conduct trials effectively.
End Use Dominance:
- Human Use: The vast majority of vaccine contract manufacturing is dedicated to Human Use, driven by public health initiatives, disease prevention programs, and the development of therapies for a wide range of infectious diseases and non-communicable conditions.
Key Drivers:
- Investment Trends: Significant capital investments are being channeled into expanding manufacturing capacity, particularly for novel vaccine platforms like mRNA. Government incentives and private equity funding are also playing a crucial role.
- Regulatory Support: Favorable regulatory environments and expedited approval pathways for critical vaccines encourage CMOs to invest in advanced technologies and expand their capabilities.
- Technological Advancements: Continuous innovation in bioprocessing, analytical techniques, and automated fill and finish technologies are driving efficiency and quality in vaccine manufacturing.
- Global Health Initiatives: The persistent threat of infectious diseases and the proactive pursuit of disease eradication programs globally necessitate robust and scalable vaccine manufacturing capabilities, often relying on contract manufacturers.
Vaccine Contract Manufacturing Industry Product Innovations
The Vaccine Contract Manufacturing Industry is a hotbed of product innovation, driven by advancements in vaccine technologies and manufacturing processes. Innovations in RNA Vaccines are particularly noteworthy, with contract manufacturers developing specialized capabilities for lipid nanoparticle (LNP) formulation and cold-chain logistics. Similarly, the refinement of Subunit Vaccines through improved antigen expression and purification techniques is enhancing product efficacy and reducing production costs. Performance metrics such as yield improvement, purity levels, and batch consistency are continuously being optimized. CMOs are also innovating in Fill and Finish operations, introducing advanced aseptic filling technologies and serialization for enhanced product integrity and traceability. The unique selling propositions of leading CMOs lie in their ability to handle complex biologics, adhere to stringent regulatory standards, and offer end-to-end manufacturing solutions from upstream processing to final packaging.
Propelling Factors for Vaccine Contract Manufacturing Industry Growth
The Vaccine Contract Manufacturing Industry is propelled by a confluence of powerful factors:
- Technological Advancements: The rapid evolution of RNA Vaccines, DNA Vaccines, and Subunit Vaccines requires specialized manufacturing expertise and infrastructure that many biotech firms outsource to CMOs. Innovations in Upstream Processing (e.g., advanced expression systems) and Downstream Processing (e.g., novel purification techniques, sterile fill and finish) are critical.
- Increasing Demand for Vaccines: A growing global population, rising incidences of infectious diseases, and the development of vaccines for non-communicable diseases are fueling demand for both existing and novel vaccines.
- Outsourcing Trend: Pharmaceutical and biotechnology companies increasingly opt to outsource manufacturing to CMOs to reduce capital expenditure, leverage specialized expertise, and accelerate time-to-market for new vaccines.
- Government Initiatives and Funding: Global health organizations and national governments are investing heavily in vaccine research, development, and manufacturing capacity, often through partnerships with CMOs.
Obstacles in the Vaccine Contract Manufacturing Industry Market
Despite robust growth, the Vaccine Contract Manufacturing Industry faces several obstacles:
- Regulatory Hurdles: The stringent and evolving regulatory requirements for vaccine production (e.g., FDA, EMA) can be costly and time-consuming to navigate, especially for new CMOs.
- Supply Chain Disruptions: Dependence on global supply chains for raw materials, specialized equipment, and excipients can lead to delays and increased costs, as seen with recent global events.
- High Capital Investment: Establishing and maintaining state-of-the-art manufacturing facilities for diverse vaccine types requires substantial capital, creating a barrier to entry.
- Skilled Workforce Shortage: The specialized nature of vaccine manufacturing necessitates a highly skilled workforce, and a shortage of experienced personnel can hamper operational efficiency.
- Intellectual Property Protection: Ensuring the robust protection of clients' intellectual property is paramount and can be a complex aspect of contract manufacturing agreements.
Future Opportunities in Vaccine Contract Manufacturing Industry
The Vaccine Contract Manufacturing Industry is replete with emerging opportunities:
- Expansion into Novel Vaccine Modalities: Significant growth potential lies in supporting the development and manufacturing of next-generation vaccines, including personalized cancer vaccines, virosome vaccines, and advanced adjuvants.
- Geographic Expansion: Emerging markets represent a growing opportunity as governments prioritize domestic vaccine production and access to essential immunizations.
- Biologics Manufacturing Integration: CMOs that can offer integrated services for both vaccine and broader biologic manufacturing will be well-positioned for growth.
- Advanced Analytics and Data Management: Leveraging AI and machine learning for process optimization, quality control, and predictive maintenance presents a significant opportunity to enhance efficiency and value.
- Sustainability Initiatives: Developing and implementing greener manufacturing processes and sustainable supply chain practices will become an increasingly important differentiator.
Major Players in the Vaccine Contract Manufacturing Industry Ecosystem
- CJ CheilJedang Corporation (Batavia Biosciences)
- Curia Global
- ICON PLC
- Charles River Laboratories International Inc
- Catalent
- IDT Biologika GmbH
- Lonza Group AG
- Gedeon Richter (Richter-Helm BioLogics)
- Ajinomoto Bio-Pharma Services
- Recipharm AB
- Emergent BioSolutions Inc
- Fujifilm Holdings Corporation
Key Developments in Vaccine Contract Manufacturing Industry Industry
- August 2022: Moderna inked an agreement with the Canadian government to construct a messenger RNA vaccine manufacturing factory in an undetermined location in Canada. According to the biotech firm, the partnership will give Canadians access to mRNA vaccines made in Canada against respiratory viruses such as SARS-CoV-2, influenza, and respiratory syncytial virus. This development signifies a significant push towards domestic mRNA vaccine production and highlights the strategic importance of contract manufacturing capabilities.
- June 2022: Merck and Agilent Technologies collaborated with each other to advance process analytical technologies for downstream processing and overcome the gaps within downstream processing. This collaboration underscores the ongoing industry focus on improving efficiency, quality, and real-time monitoring in critical downstream vaccine manufacturing steps.
Strategic Vaccine Contract Manufacturing Industry Market Forecast
The Vaccine Contract Manufacturing Industry is projected for robust growth, fueled by ongoing innovation in vaccine technologies and an increasing reliance on specialized manufacturing partners. Strategic opportunities lie in catering to the burgeoning demand for RNA Vaccines and other novel modalities, alongside continued strength in established Inactivated Vaccines and Subunit Vaccines. Investments in advanced downstream processing and sterile fill and finish capabilities will be crucial for CMOs to capture market share. Furthermore, the expanding global healthcare landscape and the persistent need for pandemic preparedness will create sustained demand for commercial-scale manufacturing. The forecast indicates a significant market expansion, driven by both technological advancements and global health priorities, positioning Vaccine Contract Manufacturing as a vital engine for public health worldwide, with an estimated market size in the tens of Millions.
Vaccine Contract Manufacturing Industry Segmentation
-
1. Vaccine Type
- 1.1. Inactivated Vaccines
- 1.2. Live-attenuated Vaccines
- 1.3. RNA Vaccines
- 1.4. Subunit Vaccines
- 1.5. Toxoid-based Vaccines
-
2. Process
-
2.1. Downstream
- 2.1.1. Analytical and QC Studies
- 2.1.2. Fill and Finish
- 2.1.3. Packaging
- 2.1.4. Other Downstream Processes
-
2.2. Upstream
- 2.2.1. Bacterial Expression Systems
- 2.2.2. Baculovirus/Insect Expression Systems
- 2.2.3. Mammalian Expression Systems
- 2.2.4. Yeast Expression Systems
- 2.2.5. Other Upstream Processes
-
2.1. Downstream
-
3. Scale of Operations
- 3.1. Preclinical
- 3.2. Clinical
- 3.3. Commercial
-
4. End Use
- 4.1. Human Use
- 4.2. Veterinary
Vaccine Contract Manufacturing Industry Segmentation By Geography
-
1. North America
- 1.1. United States
- 1.2. Canada
- 1.3. Mexico
-
2. Europe
- 2.1. Germany
- 2.2. United Kingdom
- 2.3. France
- 2.4. Italy
- 2.5. Spain
- 2.6. Rest of Europe
-
3. Asia Pacific
- 3.1. China
- 3.2. Japan
- 3.3. India
- 3.4. Australia
- 3.5. South Korea
- 3.6. Rest of Asia Pacific
-
4. Middle East and Africa
- 4.1. GCC
- 4.2. South Africa
- 4.3. Rest of Middle East and Africa
-
5. South America
- 5.1. Brazil
- 5.2. Argentina
- 5.3. Rest of South America
Vaccine Contract Manufacturing Industry Regional Market Share
Geographic Coverage of Vaccine Contract Manufacturing Industry
Vaccine Contract Manufacturing Industry REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2020-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2020-2025 |
| Growth Rate | CAGR of 11.18% from 2020-2034 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Advancements in Technology and Cost Benefits in Infrastructure and Operational Benefits; Increase in Initiatives Favoring Vaccinations; Favorable Patient Demographics and Growing Vaccinations of Newborns and Children
- 3.3. Market Restrains
- 3.3.1. Rising High Costs of Vaccines; Lack of Storage Infrastructure and Limitations Associated with Supply Chain
- 3.4. Market Trends
- 3.4.1. The Inactivated Vaccines Segment is Expected to Hold a Significant Share in the Vaccine Contract Manufacturing Market over the Forecast Period
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Global Vaccine Contract Manufacturing Industry Analysis, Insights and Forecast, 2020-2032
- 5.1. Market Analysis, Insights and Forecast - by Vaccine Type
- 5.1.1. Inactivated Vaccines
- 5.1.2. Live-attenuated Vaccines
- 5.1.3. RNA Vaccines
- 5.1.4. Subunit Vaccines
- 5.1.5. Toxoid-based Vaccines
- 5.2. Market Analysis, Insights and Forecast - by Process
- 5.2.1. Downstream
- 5.2.1.1. Analytical and QC Studies
- 5.2.1.2. Fill and Finish
- 5.2.1.3. Packaging
- 5.2.1.4. Other Downstream Processes
- 5.2.2. Upstream
- 5.2.2.1. Bacterial Expression Systems
- 5.2.2.2. Baculovirus/Insect Expression Systems
- 5.2.2.3. Mammalian Expression Systems
- 5.2.2.4. Yeast Expression Systems
- 5.2.2.5. Other Upstream Processes
- 5.2.1. Downstream
- 5.3. Market Analysis, Insights and Forecast - by Scale of Operations
- 5.3.1. Preclinical
- 5.3.2. Clinical
- 5.3.3. Commercial
- 5.4. Market Analysis, Insights and Forecast - by End Use
- 5.4.1. Human Use
- 5.4.2. Veterinary
- 5.5. Market Analysis, Insights and Forecast - by Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Middle East and Africa
- 5.5.5. South America
- 5.1. Market Analysis, Insights and Forecast - by Vaccine Type
- 6. North America Vaccine Contract Manufacturing Industry Analysis, Insights and Forecast, 2020-2032
- 6.1. Market Analysis, Insights and Forecast - by Vaccine Type
- 6.1.1. Inactivated Vaccines
- 6.1.2. Live-attenuated Vaccines
- 6.1.3. RNA Vaccines
- 6.1.4. Subunit Vaccines
- 6.1.5. Toxoid-based Vaccines
- 6.2. Market Analysis, Insights and Forecast - by Process
- 6.2.1. Downstream
- 6.2.1.1. Analytical and QC Studies
- 6.2.1.2. Fill and Finish
- 6.2.1.3. Packaging
- 6.2.1.4. Other Downstream Processes
- 6.2.2. Upstream
- 6.2.2.1. Bacterial Expression Systems
- 6.2.2.2. Baculovirus/Insect Expression Systems
- 6.2.2.3. Mammalian Expression Systems
- 6.2.2.4. Yeast Expression Systems
- 6.2.2.5. Other Upstream Processes
- 6.2.1. Downstream
- 6.3. Market Analysis, Insights and Forecast - by Scale of Operations
- 6.3.1. Preclinical
- 6.3.2. Clinical
- 6.3.3. Commercial
- 6.4. Market Analysis, Insights and Forecast - by End Use
- 6.4.1. Human Use
- 6.4.2. Veterinary
- 6.1. Market Analysis, Insights and Forecast - by Vaccine Type
- 7. Europe Vaccine Contract Manufacturing Industry Analysis, Insights and Forecast, 2020-2032
- 7.1. Market Analysis, Insights and Forecast - by Vaccine Type
- 7.1.1. Inactivated Vaccines
- 7.1.2. Live-attenuated Vaccines
- 7.1.3. RNA Vaccines
- 7.1.4. Subunit Vaccines
- 7.1.5. Toxoid-based Vaccines
- 7.2. Market Analysis, Insights and Forecast - by Process
- 7.2.1. Downstream
- 7.2.1.1. Analytical and QC Studies
- 7.2.1.2. Fill and Finish
- 7.2.1.3. Packaging
- 7.2.1.4. Other Downstream Processes
- 7.2.2. Upstream
- 7.2.2.1. Bacterial Expression Systems
- 7.2.2.2. Baculovirus/Insect Expression Systems
- 7.2.2.3. Mammalian Expression Systems
- 7.2.2.4. Yeast Expression Systems
- 7.2.2.5. Other Upstream Processes
- 7.2.1. Downstream
- 7.3. Market Analysis, Insights and Forecast - by Scale of Operations
- 7.3.1. Preclinical
- 7.3.2. Clinical
- 7.3.3. Commercial
- 7.4. Market Analysis, Insights and Forecast - by End Use
- 7.4.1. Human Use
- 7.4.2. Veterinary
- 7.1. Market Analysis, Insights and Forecast - by Vaccine Type
- 8. Asia Pacific Vaccine Contract Manufacturing Industry Analysis, Insights and Forecast, 2020-2032
- 8.1. Market Analysis, Insights and Forecast - by Vaccine Type
- 8.1.1. Inactivated Vaccines
- 8.1.2. Live-attenuated Vaccines
- 8.1.3. RNA Vaccines
- 8.1.4. Subunit Vaccines
- 8.1.5. Toxoid-based Vaccines
- 8.2. Market Analysis, Insights and Forecast - by Process
- 8.2.1. Downstream
- 8.2.1.1. Analytical and QC Studies
- 8.2.1.2. Fill and Finish
- 8.2.1.3. Packaging
- 8.2.1.4. Other Downstream Processes
- 8.2.2. Upstream
- 8.2.2.1. Bacterial Expression Systems
- 8.2.2.2. Baculovirus/Insect Expression Systems
- 8.2.2.3. Mammalian Expression Systems
- 8.2.2.4. Yeast Expression Systems
- 8.2.2.5. Other Upstream Processes
- 8.2.1. Downstream
- 8.3. Market Analysis, Insights and Forecast - by Scale of Operations
- 8.3.1. Preclinical
- 8.3.2. Clinical
- 8.3.3. Commercial
- 8.4. Market Analysis, Insights and Forecast - by End Use
- 8.4.1. Human Use
- 8.4.2. Veterinary
- 8.1. Market Analysis, Insights and Forecast - by Vaccine Type
- 9. Middle East and Africa Vaccine Contract Manufacturing Industry Analysis, Insights and Forecast, 2020-2032
- 9.1. Market Analysis, Insights and Forecast - by Vaccine Type
- 9.1.1. Inactivated Vaccines
- 9.1.2. Live-attenuated Vaccines
- 9.1.3. RNA Vaccines
- 9.1.4. Subunit Vaccines
- 9.1.5. Toxoid-based Vaccines
- 9.2. Market Analysis, Insights and Forecast - by Process
- 9.2.1. Downstream
- 9.2.1.1. Analytical and QC Studies
- 9.2.1.2. Fill and Finish
- 9.2.1.3. Packaging
- 9.2.1.4. Other Downstream Processes
- 9.2.2. Upstream
- 9.2.2.1. Bacterial Expression Systems
- 9.2.2.2. Baculovirus/Insect Expression Systems
- 9.2.2.3. Mammalian Expression Systems
- 9.2.2.4. Yeast Expression Systems
- 9.2.2.5. Other Upstream Processes
- 9.2.1. Downstream
- 9.3. Market Analysis, Insights and Forecast - by Scale of Operations
- 9.3.1. Preclinical
- 9.3.2. Clinical
- 9.3.3. Commercial
- 9.4. Market Analysis, Insights and Forecast - by End Use
- 9.4.1. Human Use
- 9.4.2. Veterinary
- 9.1. Market Analysis, Insights and Forecast - by Vaccine Type
- 10. South America Vaccine Contract Manufacturing Industry Analysis, Insights and Forecast, 2020-2032
- 10.1. Market Analysis, Insights and Forecast - by Vaccine Type
- 10.1.1. Inactivated Vaccines
- 10.1.2. Live-attenuated Vaccines
- 10.1.3. RNA Vaccines
- 10.1.4. Subunit Vaccines
- 10.1.5. Toxoid-based Vaccines
- 10.2. Market Analysis, Insights and Forecast - by Process
- 10.2.1. Downstream
- 10.2.1.1. Analytical and QC Studies
- 10.2.1.2. Fill and Finish
- 10.2.1.3. Packaging
- 10.2.1.4. Other Downstream Processes
- 10.2.2. Upstream
- 10.2.2.1. Bacterial Expression Systems
- 10.2.2.2. Baculovirus/Insect Expression Systems
- 10.2.2.3. Mammalian Expression Systems
- 10.2.2.4. Yeast Expression Systems
- 10.2.2.5. Other Upstream Processes
- 10.2.1. Downstream
- 10.3. Market Analysis, Insights and Forecast - by Scale of Operations
- 10.3.1. Preclinical
- 10.3.2. Clinical
- 10.3.3. Commercial
- 10.4. Market Analysis, Insights and Forecast - by End Use
- 10.4.1. Human Use
- 10.4.2. Veterinary
- 10.1. Market Analysis, Insights and Forecast - by Vaccine Type
- 11. Competitive Analysis
- 11.1. Global Market Share Analysis 2025
- 11.2. Company Profiles
- 11.2.1 CJ CheilJedang Corporation (Batavia Biosciences)
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Financials (Based on Availability)
- 11.2.2 Curia Global
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Financials (Based on Availability)
- 11.2.3 ICON PLC
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Financials (Based on Availability)
- 11.2.4 Charles River Laboratories International Inc
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Financials (Based on Availability)
- 11.2.5 Catalent
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Financials (Based on Availability)
- 11.2.6 IDT Biologika GmbH
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Financials (Based on Availability)
- 11.2.7 Lonza Group AG
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Financials (Based on Availability)
- 11.2.8 Gedeon Richter (Richter-Helm BioLogics)
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Financials (Based on Availability)
- 11.2.9 Ajinomoto Bio-Pharma Services
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Financials (Based on Availability)
- 11.2.10 Recipharm AB
- 11.2.10.1. Overview
- 11.2.10.2. Products
- 11.2.10.3. SWOT Analysis
- 11.2.10.4. Recent Developments
- 11.2.10.5. Financials (Based on Availability)
- 11.2.11 Emergent BioSolutions Inc
- 11.2.11.1. Overview
- 11.2.11.2. Products
- 11.2.11.3. SWOT Analysis
- 11.2.11.4. Recent Developments
- 11.2.11.5. Financials (Based on Availability)
- 11.2.12 Fujifilm Holdings Corporation
- 11.2.12.1. Overview
- 11.2.12.2. Products
- 11.2.12.3. SWOT Analysis
- 11.2.12.4. Recent Developments
- 11.2.12.5. Financials (Based on Availability)
- 11.2.1 CJ CheilJedang Corporation (Batavia Biosciences)
List of Figures
- Figure 1: Global Vaccine Contract Manufacturing Industry Revenue Breakdown (Million, %) by Region 2025 & 2033
- Figure 2: Global Vaccine Contract Manufacturing Industry Volume Breakdown (K Unit, %) by Region 2025 & 2033
- Figure 3: North America Vaccine Contract Manufacturing Industry Revenue (Million), by Vaccine Type 2025 & 2033
- Figure 4: North America Vaccine Contract Manufacturing Industry Volume (K Unit), by Vaccine Type 2025 & 2033
- Figure 5: North America Vaccine Contract Manufacturing Industry Revenue Share (%), by Vaccine Type 2025 & 2033
- Figure 6: North America Vaccine Contract Manufacturing Industry Volume Share (%), by Vaccine Type 2025 & 2033
- Figure 7: North America Vaccine Contract Manufacturing Industry Revenue (Million), by Process 2025 & 2033
- Figure 8: North America Vaccine Contract Manufacturing Industry Volume (K Unit), by Process 2025 & 2033
- Figure 9: North America Vaccine Contract Manufacturing Industry Revenue Share (%), by Process 2025 & 2033
- Figure 10: North America Vaccine Contract Manufacturing Industry Volume Share (%), by Process 2025 & 2033
- Figure 11: North America Vaccine Contract Manufacturing Industry Revenue (Million), by Scale of Operations 2025 & 2033
- Figure 12: North America Vaccine Contract Manufacturing Industry Volume (K Unit), by Scale of Operations 2025 & 2033
- Figure 13: North America Vaccine Contract Manufacturing Industry Revenue Share (%), by Scale of Operations 2025 & 2033
- Figure 14: North America Vaccine Contract Manufacturing Industry Volume Share (%), by Scale of Operations 2025 & 2033
- Figure 15: North America Vaccine Contract Manufacturing Industry Revenue (Million), by End Use 2025 & 2033
- Figure 16: North America Vaccine Contract Manufacturing Industry Volume (K Unit), by End Use 2025 & 2033
- Figure 17: North America Vaccine Contract Manufacturing Industry Revenue Share (%), by End Use 2025 & 2033
- Figure 18: North America Vaccine Contract Manufacturing Industry Volume Share (%), by End Use 2025 & 2033
- Figure 19: North America Vaccine Contract Manufacturing Industry Revenue (Million), by Country 2025 & 2033
- Figure 20: North America Vaccine Contract Manufacturing Industry Volume (K Unit), by Country 2025 & 2033
- Figure 21: North America Vaccine Contract Manufacturing Industry Revenue Share (%), by Country 2025 & 2033
- Figure 22: North America Vaccine Contract Manufacturing Industry Volume Share (%), by Country 2025 & 2033
- Figure 23: Europe Vaccine Contract Manufacturing Industry Revenue (Million), by Vaccine Type 2025 & 2033
- Figure 24: Europe Vaccine Contract Manufacturing Industry Volume (K Unit), by Vaccine Type 2025 & 2033
- Figure 25: Europe Vaccine Contract Manufacturing Industry Revenue Share (%), by Vaccine Type 2025 & 2033
- Figure 26: Europe Vaccine Contract Manufacturing Industry Volume Share (%), by Vaccine Type 2025 & 2033
- Figure 27: Europe Vaccine Contract Manufacturing Industry Revenue (Million), by Process 2025 & 2033
- Figure 28: Europe Vaccine Contract Manufacturing Industry Volume (K Unit), by Process 2025 & 2033
- Figure 29: Europe Vaccine Contract Manufacturing Industry Revenue Share (%), by Process 2025 & 2033
- Figure 30: Europe Vaccine Contract Manufacturing Industry Volume Share (%), by Process 2025 & 2033
- Figure 31: Europe Vaccine Contract Manufacturing Industry Revenue (Million), by Scale of Operations 2025 & 2033
- Figure 32: Europe Vaccine Contract Manufacturing Industry Volume (K Unit), by Scale of Operations 2025 & 2033
- Figure 33: Europe Vaccine Contract Manufacturing Industry Revenue Share (%), by Scale of Operations 2025 & 2033
- Figure 34: Europe Vaccine Contract Manufacturing Industry Volume Share (%), by Scale of Operations 2025 & 2033
- Figure 35: Europe Vaccine Contract Manufacturing Industry Revenue (Million), by End Use 2025 & 2033
- Figure 36: Europe Vaccine Contract Manufacturing Industry Volume (K Unit), by End Use 2025 & 2033
- Figure 37: Europe Vaccine Contract Manufacturing Industry Revenue Share (%), by End Use 2025 & 2033
- Figure 38: Europe Vaccine Contract Manufacturing Industry Volume Share (%), by End Use 2025 & 2033
- Figure 39: Europe Vaccine Contract Manufacturing Industry Revenue (Million), by Country 2025 & 2033
- Figure 40: Europe Vaccine Contract Manufacturing Industry Volume (K Unit), by Country 2025 & 2033
- Figure 41: Europe Vaccine Contract Manufacturing Industry Revenue Share (%), by Country 2025 & 2033
- Figure 42: Europe Vaccine Contract Manufacturing Industry Volume Share (%), by Country 2025 & 2033
- Figure 43: Asia Pacific Vaccine Contract Manufacturing Industry Revenue (Million), by Vaccine Type 2025 & 2033
- Figure 44: Asia Pacific Vaccine Contract Manufacturing Industry Volume (K Unit), by Vaccine Type 2025 & 2033
- Figure 45: Asia Pacific Vaccine Contract Manufacturing Industry Revenue Share (%), by Vaccine Type 2025 & 2033
- Figure 46: Asia Pacific Vaccine Contract Manufacturing Industry Volume Share (%), by Vaccine Type 2025 & 2033
- Figure 47: Asia Pacific Vaccine Contract Manufacturing Industry Revenue (Million), by Process 2025 & 2033
- Figure 48: Asia Pacific Vaccine Contract Manufacturing Industry Volume (K Unit), by Process 2025 & 2033
- Figure 49: Asia Pacific Vaccine Contract Manufacturing Industry Revenue Share (%), by Process 2025 & 2033
- Figure 50: Asia Pacific Vaccine Contract Manufacturing Industry Volume Share (%), by Process 2025 & 2033
- Figure 51: Asia Pacific Vaccine Contract Manufacturing Industry Revenue (Million), by Scale of Operations 2025 & 2033
- Figure 52: Asia Pacific Vaccine Contract Manufacturing Industry Volume (K Unit), by Scale of Operations 2025 & 2033
- Figure 53: Asia Pacific Vaccine Contract Manufacturing Industry Revenue Share (%), by Scale of Operations 2025 & 2033
- Figure 54: Asia Pacific Vaccine Contract Manufacturing Industry Volume Share (%), by Scale of Operations 2025 & 2033
- Figure 55: Asia Pacific Vaccine Contract Manufacturing Industry Revenue (Million), by End Use 2025 & 2033
- Figure 56: Asia Pacific Vaccine Contract Manufacturing Industry Volume (K Unit), by End Use 2025 & 2033
- Figure 57: Asia Pacific Vaccine Contract Manufacturing Industry Revenue Share (%), by End Use 2025 & 2033
- Figure 58: Asia Pacific Vaccine Contract Manufacturing Industry Volume Share (%), by End Use 2025 & 2033
- Figure 59: Asia Pacific Vaccine Contract Manufacturing Industry Revenue (Million), by Country 2025 & 2033
- Figure 60: Asia Pacific Vaccine Contract Manufacturing Industry Volume (K Unit), by Country 2025 & 2033
- Figure 61: Asia Pacific Vaccine Contract Manufacturing Industry Revenue Share (%), by Country 2025 & 2033
- Figure 62: Asia Pacific Vaccine Contract Manufacturing Industry Volume Share (%), by Country 2025 & 2033
- Figure 63: Middle East and Africa Vaccine Contract Manufacturing Industry Revenue (Million), by Vaccine Type 2025 & 2033
- Figure 64: Middle East and Africa Vaccine Contract Manufacturing Industry Volume (K Unit), by Vaccine Type 2025 & 2033
- Figure 65: Middle East and Africa Vaccine Contract Manufacturing Industry Revenue Share (%), by Vaccine Type 2025 & 2033
- Figure 66: Middle East and Africa Vaccine Contract Manufacturing Industry Volume Share (%), by Vaccine Type 2025 & 2033
- Figure 67: Middle East and Africa Vaccine Contract Manufacturing Industry Revenue (Million), by Process 2025 & 2033
- Figure 68: Middle East and Africa Vaccine Contract Manufacturing Industry Volume (K Unit), by Process 2025 & 2033
- Figure 69: Middle East and Africa Vaccine Contract Manufacturing Industry Revenue Share (%), by Process 2025 & 2033
- Figure 70: Middle East and Africa Vaccine Contract Manufacturing Industry Volume Share (%), by Process 2025 & 2033
- Figure 71: Middle East and Africa Vaccine Contract Manufacturing Industry Revenue (Million), by Scale of Operations 2025 & 2033
- Figure 72: Middle East and Africa Vaccine Contract Manufacturing Industry Volume (K Unit), by Scale of Operations 2025 & 2033
- Figure 73: Middle East and Africa Vaccine Contract Manufacturing Industry Revenue Share (%), by Scale of Operations 2025 & 2033
- Figure 74: Middle East and Africa Vaccine Contract Manufacturing Industry Volume Share (%), by Scale of Operations 2025 & 2033
- Figure 75: Middle East and Africa Vaccine Contract Manufacturing Industry Revenue (Million), by End Use 2025 & 2033
- Figure 76: Middle East and Africa Vaccine Contract Manufacturing Industry Volume (K Unit), by End Use 2025 & 2033
- Figure 77: Middle East and Africa Vaccine Contract Manufacturing Industry Revenue Share (%), by End Use 2025 & 2033
- Figure 78: Middle East and Africa Vaccine Contract Manufacturing Industry Volume Share (%), by End Use 2025 & 2033
- Figure 79: Middle East and Africa Vaccine Contract Manufacturing Industry Revenue (Million), by Country 2025 & 2033
- Figure 80: Middle East and Africa Vaccine Contract Manufacturing Industry Volume (K Unit), by Country 2025 & 2033
- Figure 81: Middle East and Africa Vaccine Contract Manufacturing Industry Revenue Share (%), by Country 2025 & 2033
- Figure 82: Middle East and Africa Vaccine Contract Manufacturing Industry Volume Share (%), by Country 2025 & 2033
- Figure 83: South America Vaccine Contract Manufacturing Industry Revenue (Million), by Vaccine Type 2025 & 2033
- Figure 84: South America Vaccine Contract Manufacturing Industry Volume (K Unit), by Vaccine Type 2025 & 2033
- Figure 85: South America Vaccine Contract Manufacturing Industry Revenue Share (%), by Vaccine Type 2025 & 2033
- Figure 86: South America Vaccine Contract Manufacturing Industry Volume Share (%), by Vaccine Type 2025 & 2033
- Figure 87: South America Vaccine Contract Manufacturing Industry Revenue (Million), by Process 2025 & 2033
- Figure 88: South America Vaccine Contract Manufacturing Industry Volume (K Unit), by Process 2025 & 2033
- Figure 89: South America Vaccine Contract Manufacturing Industry Revenue Share (%), by Process 2025 & 2033
- Figure 90: South America Vaccine Contract Manufacturing Industry Volume Share (%), by Process 2025 & 2033
- Figure 91: South America Vaccine Contract Manufacturing Industry Revenue (Million), by Scale of Operations 2025 & 2033
- Figure 92: South America Vaccine Contract Manufacturing Industry Volume (K Unit), by Scale of Operations 2025 & 2033
- Figure 93: South America Vaccine Contract Manufacturing Industry Revenue Share (%), by Scale of Operations 2025 & 2033
- Figure 94: South America Vaccine Contract Manufacturing Industry Volume Share (%), by Scale of Operations 2025 & 2033
- Figure 95: South America Vaccine Contract Manufacturing Industry Revenue (Million), by End Use 2025 & 2033
- Figure 96: South America Vaccine Contract Manufacturing Industry Volume (K Unit), by End Use 2025 & 2033
- Figure 97: South America Vaccine Contract Manufacturing Industry Revenue Share (%), by End Use 2025 & 2033
- Figure 98: South America Vaccine Contract Manufacturing Industry Volume Share (%), by End Use 2025 & 2033
- Figure 99: South America Vaccine Contract Manufacturing Industry Revenue (Million), by Country 2025 & 2033
- Figure 100: South America Vaccine Contract Manufacturing Industry Volume (K Unit), by Country 2025 & 2033
- Figure 101: South America Vaccine Contract Manufacturing Industry Revenue Share (%), by Country 2025 & 2033
- Figure 102: South America Vaccine Contract Manufacturing Industry Volume Share (%), by Country 2025 & 2033
List of Tables
- Table 1: Global Vaccine Contract Manufacturing Industry Revenue Million Forecast, by Vaccine Type 2020 & 2033
- Table 2: Global Vaccine Contract Manufacturing Industry Volume K Unit Forecast, by Vaccine Type 2020 & 2033
- Table 3: Global Vaccine Contract Manufacturing Industry Revenue Million Forecast, by Process 2020 & 2033
- Table 4: Global Vaccine Contract Manufacturing Industry Volume K Unit Forecast, by Process 2020 & 2033
- Table 5: Global Vaccine Contract Manufacturing Industry Revenue Million Forecast, by Scale of Operations 2020 & 2033
- Table 6: Global Vaccine Contract Manufacturing Industry Volume K Unit Forecast, by Scale of Operations 2020 & 2033
- Table 7: Global Vaccine Contract Manufacturing Industry Revenue Million Forecast, by End Use 2020 & 2033
- Table 8: Global Vaccine Contract Manufacturing Industry Volume K Unit Forecast, by End Use 2020 & 2033
- Table 9: Global Vaccine Contract Manufacturing Industry Revenue Million Forecast, by Region 2020 & 2033
- Table 10: Global Vaccine Contract Manufacturing Industry Volume K Unit Forecast, by Region 2020 & 2033
- Table 11: Global Vaccine Contract Manufacturing Industry Revenue Million Forecast, by Vaccine Type 2020 & 2033
- Table 12: Global Vaccine Contract Manufacturing Industry Volume K Unit Forecast, by Vaccine Type 2020 & 2033
- Table 13: Global Vaccine Contract Manufacturing Industry Revenue Million Forecast, by Process 2020 & 2033
- Table 14: Global Vaccine Contract Manufacturing Industry Volume K Unit Forecast, by Process 2020 & 2033
- Table 15: Global Vaccine Contract Manufacturing Industry Revenue Million Forecast, by Scale of Operations 2020 & 2033
- Table 16: Global Vaccine Contract Manufacturing Industry Volume K Unit Forecast, by Scale of Operations 2020 & 2033
- Table 17: Global Vaccine Contract Manufacturing Industry Revenue Million Forecast, by End Use 2020 & 2033
- Table 18: Global Vaccine Contract Manufacturing Industry Volume K Unit Forecast, by End Use 2020 & 2033
- Table 19: Global Vaccine Contract Manufacturing Industry Revenue Million Forecast, by Country 2020 & 2033
- Table 20: Global Vaccine Contract Manufacturing Industry Volume K Unit Forecast, by Country 2020 & 2033
- Table 21: United States Vaccine Contract Manufacturing Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 22: United States Vaccine Contract Manufacturing Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 23: Canada Vaccine Contract Manufacturing Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 24: Canada Vaccine Contract Manufacturing Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 25: Mexico Vaccine Contract Manufacturing Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 26: Mexico Vaccine Contract Manufacturing Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 27: Global Vaccine Contract Manufacturing Industry Revenue Million Forecast, by Vaccine Type 2020 & 2033
- Table 28: Global Vaccine Contract Manufacturing Industry Volume K Unit Forecast, by Vaccine Type 2020 & 2033
- Table 29: Global Vaccine Contract Manufacturing Industry Revenue Million Forecast, by Process 2020 & 2033
- Table 30: Global Vaccine Contract Manufacturing Industry Volume K Unit Forecast, by Process 2020 & 2033
- Table 31: Global Vaccine Contract Manufacturing Industry Revenue Million Forecast, by Scale of Operations 2020 & 2033
- Table 32: Global Vaccine Contract Manufacturing Industry Volume K Unit Forecast, by Scale of Operations 2020 & 2033
- Table 33: Global Vaccine Contract Manufacturing Industry Revenue Million Forecast, by End Use 2020 & 2033
- Table 34: Global Vaccine Contract Manufacturing Industry Volume K Unit Forecast, by End Use 2020 & 2033
- Table 35: Global Vaccine Contract Manufacturing Industry Revenue Million Forecast, by Country 2020 & 2033
- Table 36: Global Vaccine Contract Manufacturing Industry Volume K Unit Forecast, by Country 2020 & 2033
- Table 37: Germany Vaccine Contract Manufacturing Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 38: Germany Vaccine Contract Manufacturing Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 39: United Kingdom Vaccine Contract Manufacturing Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 40: United Kingdom Vaccine Contract Manufacturing Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 41: France Vaccine Contract Manufacturing Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 42: France Vaccine Contract Manufacturing Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 43: Italy Vaccine Contract Manufacturing Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 44: Italy Vaccine Contract Manufacturing Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 45: Spain Vaccine Contract Manufacturing Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 46: Spain Vaccine Contract Manufacturing Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 47: Rest of Europe Vaccine Contract Manufacturing Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 48: Rest of Europe Vaccine Contract Manufacturing Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 49: Global Vaccine Contract Manufacturing Industry Revenue Million Forecast, by Vaccine Type 2020 & 2033
- Table 50: Global Vaccine Contract Manufacturing Industry Volume K Unit Forecast, by Vaccine Type 2020 & 2033
- Table 51: Global Vaccine Contract Manufacturing Industry Revenue Million Forecast, by Process 2020 & 2033
- Table 52: Global Vaccine Contract Manufacturing Industry Volume K Unit Forecast, by Process 2020 & 2033
- Table 53: Global Vaccine Contract Manufacturing Industry Revenue Million Forecast, by Scale of Operations 2020 & 2033
- Table 54: Global Vaccine Contract Manufacturing Industry Volume K Unit Forecast, by Scale of Operations 2020 & 2033
- Table 55: Global Vaccine Contract Manufacturing Industry Revenue Million Forecast, by End Use 2020 & 2033
- Table 56: Global Vaccine Contract Manufacturing Industry Volume K Unit Forecast, by End Use 2020 & 2033
- Table 57: Global Vaccine Contract Manufacturing Industry Revenue Million Forecast, by Country 2020 & 2033
- Table 58: Global Vaccine Contract Manufacturing Industry Volume K Unit Forecast, by Country 2020 & 2033
- Table 59: China Vaccine Contract Manufacturing Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 60: China Vaccine Contract Manufacturing Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 61: Japan Vaccine Contract Manufacturing Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 62: Japan Vaccine Contract Manufacturing Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 63: India Vaccine Contract Manufacturing Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 64: India Vaccine Contract Manufacturing Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 65: Australia Vaccine Contract Manufacturing Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 66: Australia Vaccine Contract Manufacturing Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 67: South Korea Vaccine Contract Manufacturing Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 68: South Korea Vaccine Contract Manufacturing Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 69: Rest of Asia Pacific Vaccine Contract Manufacturing Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 70: Rest of Asia Pacific Vaccine Contract Manufacturing Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 71: Global Vaccine Contract Manufacturing Industry Revenue Million Forecast, by Vaccine Type 2020 & 2033
- Table 72: Global Vaccine Contract Manufacturing Industry Volume K Unit Forecast, by Vaccine Type 2020 & 2033
- Table 73: Global Vaccine Contract Manufacturing Industry Revenue Million Forecast, by Process 2020 & 2033
- Table 74: Global Vaccine Contract Manufacturing Industry Volume K Unit Forecast, by Process 2020 & 2033
- Table 75: Global Vaccine Contract Manufacturing Industry Revenue Million Forecast, by Scale of Operations 2020 & 2033
- Table 76: Global Vaccine Contract Manufacturing Industry Volume K Unit Forecast, by Scale of Operations 2020 & 2033
- Table 77: Global Vaccine Contract Manufacturing Industry Revenue Million Forecast, by End Use 2020 & 2033
- Table 78: Global Vaccine Contract Manufacturing Industry Volume K Unit Forecast, by End Use 2020 & 2033
- Table 79: Global Vaccine Contract Manufacturing Industry Revenue Million Forecast, by Country 2020 & 2033
- Table 80: Global Vaccine Contract Manufacturing Industry Volume K Unit Forecast, by Country 2020 & 2033
- Table 81: GCC Vaccine Contract Manufacturing Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 82: GCC Vaccine Contract Manufacturing Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 83: South Africa Vaccine Contract Manufacturing Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 84: South Africa Vaccine Contract Manufacturing Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 85: Rest of Middle East and Africa Vaccine Contract Manufacturing Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 86: Rest of Middle East and Africa Vaccine Contract Manufacturing Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 87: Global Vaccine Contract Manufacturing Industry Revenue Million Forecast, by Vaccine Type 2020 & 2033
- Table 88: Global Vaccine Contract Manufacturing Industry Volume K Unit Forecast, by Vaccine Type 2020 & 2033
- Table 89: Global Vaccine Contract Manufacturing Industry Revenue Million Forecast, by Process 2020 & 2033
- Table 90: Global Vaccine Contract Manufacturing Industry Volume K Unit Forecast, by Process 2020 & 2033
- Table 91: Global Vaccine Contract Manufacturing Industry Revenue Million Forecast, by Scale of Operations 2020 & 2033
- Table 92: Global Vaccine Contract Manufacturing Industry Volume K Unit Forecast, by Scale of Operations 2020 & 2033
- Table 93: Global Vaccine Contract Manufacturing Industry Revenue Million Forecast, by End Use 2020 & 2033
- Table 94: Global Vaccine Contract Manufacturing Industry Volume K Unit Forecast, by End Use 2020 & 2033
- Table 95: Global Vaccine Contract Manufacturing Industry Revenue Million Forecast, by Country 2020 & 2033
- Table 96: Global Vaccine Contract Manufacturing Industry Volume K Unit Forecast, by Country 2020 & 2033
- Table 97: Brazil Vaccine Contract Manufacturing Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 98: Brazil Vaccine Contract Manufacturing Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 99: Argentina Vaccine Contract Manufacturing Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 100: Argentina Vaccine Contract Manufacturing Industry Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 101: Rest of South America Vaccine Contract Manufacturing Industry Revenue (Million) Forecast, by Application 2020 & 2033
- Table 102: Rest of South America Vaccine Contract Manufacturing Industry Volume (K Unit) Forecast, by Application 2020 & 2033
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Vaccine Contract Manufacturing Industry?
The projected CAGR is approximately 11.18%.
2. Which companies are prominent players in the Vaccine Contract Manufacturing Industry?
Key companies in the market include CJ CheilJedang Corporation (Batavia Biosciences), Curia Global, ICON PLC, Charles River Laboratories International Inc, Catalent, IDT Biologika GmbH, Lonza Group AG, Gedeon Richter (Richter-Helm BioLogics), Ajinomoto Bio-Pharma Services, Recipharm AB, Emergent BioSolutions Inc, Fujifilm Holdings Corporation.
3. What are the main segments of the Vaccine Contract Manufacturing Industry?
The market segments include Vaccine Type, Process, Scale of Operations, End Use.
4. Can you provide details about the market size?
The market size is estimated to be USD 3.51 Million as of 2022.
5. What are some drivers contributing to market growth?
Advancements in Technology and Cost Benefits in Infrastructure and Operational Benefits; Increase in Initiatives Favoring Vaccinations; Favorable Patient Demographics and Growing Vaccinations of Newborns and Children.
6. What are the notable trends driving market growth?
The Inactivated Vaccines Segment is Expected to Hold a Significant Share in the Vaccine Contract Manufacturing Market over the Forecast Period.
7. Are there any restraints impacting market growth?
Rising High Costs of Vaccines; Lack of Storage Infrastructure and Limitations Associated with Supply Chain.
8. Can you provide examples of recent developments in the market?
August 2022: Moderna inked an agreement with the Canadian government to construct a messenger RNA vaccine manufacturing factory in an undetermined location in Canada. According to the biotech firm, the partnership will give Canadians access to mRNA vaccines made in Canada against respiratory viruses such as SARS-CoV-2, influenza, and respiratory syncytial virus.
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in Million and volume, measured in K Unit.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Vaccine Contract Manufacturing Industry," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Vaccine Contract Manufacturing Industry report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Vaccine Contract Manufacturing Industry?
To stay informed about further developments, trends, and reports in the Vaccine Contract Manufacturing Industry, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence